The hemophilia clinical trial pipeline is rapidly expanding, with over 50 companies developing more than 55 drugs targeting hemophilia. Key players like Novo Nordisk, Roche, and Regeneron are advancing therapies including gene editing and long-acting factor replacements. These innovations promise improved treatment options with fewer interventions, potentially transforming patient care. Upcoming clinical trials and regulatory submissions in 2026-2027 indicate continued momentum in this field.
Novo Nordisk has initiated a share repurchase programme worth up to DKK 15 billion, starting from February 4, 2026, and running for 12 months. As of May 22, 2026, the company has repurchased over 17 million B shares at an average price of DKK 262.22 ...
Novo Nordisk's POSEIDON study of 18,904 patients across 18 countries found that 40% of people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure have cardiovascular inflammation. This inflammation, mea...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
